In stock
Phesgo 80,40 mg/ml Solution for injection 15ml Vial
In stock
Only 1 left
SKU
10331014343
Phesgo is a groundbreaking targeted therapy for HER2-positive breast cancer, combining pertuzumab and trastuzumab with hyaluronidase-zzxf for subcutaneous administration. This innovative formulation dramatically reduces administration time compared to traditional IV infusions. Administered by a healthcare professional, Phesgo offers convenience and effective treatment against HER2-positive cancer cells.
Product Overview
Phesgo is a groundbreaking targeted therapy designed for the treatment of HER2-positive breast cancer. It combines two monoclonal antibodies, pertuzumab and trastuzumab, with hyaluronidase-zzxf, allowing for subcutaneous administration.
This innovative co-formulation significantly reduces administration time compared to traditional intravenous infusions, enhancing convenience for patients and healthcare providers.
Benefits of Phesgo
Phesgo offers several key advantages in the management of HER2-positive breast cancer:
- Targeted and effective therapy against HER2-positive cancer cells.
- Subcutaneous administration, dramatically reducing the time spent in clinic for drug infusion compared to IV forms.
- Convenient co-formulation of two established anti-HER2 antibodies (pertuzumab and trastuzumab).
- Aids in improving the overall patient experience during treatment.
How to Use
Phesgo is administered by a qualified healthcare professional via subcutaneous injection.
- The appropriate dose of Phesgo is determined by your physician based on your specific medical condition and treatment plan.
- The injection is typically given in the thigh over a few minutes.
- It is administered as part of a comprehensive treatment regimen for HER2-positive breast cancer.
- Regular monitoring by your healthcare team is essential throughout the course of treatment.
Caution & Warnings
It is crucial to be aware of the following important considerations when using Phesgo:
- Patients should be monitored for signs and symptoms of cardiac dysfunction, including congestive heart failure.
- Monitor for pulmonary toxicity, including interstitial lung disease or pneumonitis.
- Phesgo can cause embryo-fetal harm; effective contraception should be used during treatment and for a period after the last dose.
- Infusion-related reactions and hypersensitivity reactions, including anaphylaxis, may occur.
- This medication must not be administered intravenously.
- Not interchangeable with IV pertuzumab, trastuzumab, or other trastuzumab products.
- Do not shake the vial, as this can damage the protein.
- Administer only under the supervision of a healthcare professional experienced in the administration of antineoplastic agents.
Ingredients
Each 15ml vial of Phesgo solution contains:
- Pertuzumab
- Trastuzumab
- Hyaluronidase-zzxf
- Inactive ingredients: L-histidine, L-histidine hydrochloride monohydrate, alpha,alpha-trehalose dihydrate, L-methionine, and polysorbate 20.
Product Details
Phesgo is a sterile, preservative-free solution provided in a single-dose vial for subcutaneous administration. The solution is clear to opalescent and colorless to brownish-yellow. Each vial contains 15ml of the solution with a specific concentration of pertuzumab and trastuzumab (80 mg/ml and 40 mg/ml respectively). It is intended for professional use in a clinical setting.
| Gtin | 2308222531 |
|---|---|
| Recommended Sale Price | 25814.85 |
| Is Wasfaty Product | No |
| Brand | Not Defined |
| Ingredient Name | PERTUZUMAB,Trastuzumab |
| SFDA Reg. No | 2308222531 |
| IBC | 2308222531 |
| Drug Type | Prescription |
| Scientific Name | Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf |
| Strength | 80,40 |
| Strength Unit | mg/ml |
| Form | Solution for injection |
| Admin Route | Subcutaneous |
| Size | 15 |
| Size Unit | ml |
| Package Types | Vial |
| Package Size | 1 vial |
| shelfLife | 24 months |
| Storage conditions | Store in a refrigerator (2C to 8C). Do not freeze. |
| Refrigerator Storage | Yes |
Products you might like
